Moleculin Biotech Inc. announced that the Australian Patent Office has granted Patent No. 2024203598, titled "PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE." The patent covers certain preliposomal Annamycin lyophilizates with improved stability and high purity, with a base term extending until June 2040, subject to possible extension for regulatory approval. This development expands the company's intellectual property portfolio for Annamycin, a novel drug candidate being developed for hard-to-treat cancers including acute myeloid leukemia and soft tissue sarcoma lung metastases. Similar patents have previously been issued in the U.S. and allowed in Europe, with additional applications pending in other major markets.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-032076), on October 29, 2025, and is solely responsible for the information contained therein.